244 related articles for article (PubMed ID: 35158468)
1. COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.
Barzegar M; Mirmosayyeb O; Ebrahimi N; Bagherieh S; Afshari-Safavi A; Hosseinabadi AM; Shaygannejad V; Asgari N
Mult Scler Relat Disord; 2022 Jan; 57():103359. PubMed ID: 35158468
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434
[TBL] [Abstract][Full Text] [Related]
3. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis.
Bagherieh S; Afshari-Safavi A; Vaheb S; Kiani M; Ghaffary EM; Barzegar M; Shaygannejad V; Zabeti A; Mirmosayyeb O
Neurol Sci; 2023 Jun; 44(6):1905-1915. PubMed ID: 36745300
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of cognitive impairment in patients with neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis.
Moghadasi AN; Mirmosayyeb O; Mohammadi A; Sahraian MA; Ghajarzadeh M
Mult Scler Relat Disord; 2021 Apr; 49():102757. PubMed ID: 33486400
[TBL] [Abstract][Full Text] [Related]
5. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know?
Paybast S; Emami A; Baghalha F; Naser Moghadasi A
Mult Scler Relat Disord; 2022 Sep; 65():103960. PubMed ID: 35763914
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry.
Newsome SD; Cross AH; Fox RJ; Halper J; Kanellis P; Bebo B; Li D; Cutter GR; Rammohan KW; Salter A
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429342
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI
Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758
[TBL] [Abstract][Full Text] [Related]
8. Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): A case report-based systematic review.
Mirmosayyeb O; Ghaffary EM; Bagherieh S; Barzegar M; Dehghan MS; Shaygannejad V
Mult Scler Relat Disord; 2022 Apr; 60():103697. PubMed ID: 35306242
[TBL] [Abstract][Full Text] [Related]
9. New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review.
Harel T; Gorman EF; Wallin MT
Front Neurol; 2023; 14():1099758. PubMed ID: 37426444
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
11. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D status and neuromyelitis optica spectrum disease: A systematic review and meta-analysis.
Zhu Y; Cao S; Hu F; Zhou X; Xue Q
Clin Neurol Neurosurg; 2024 Apr; 239():108190. PubMed ID: 38520792
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
[TBL] [Abstract][Full Text] [Related]
14. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.
Louapre C; Maillart E; Papeix C; Zeidan S; Biotti D; Lepine Z; Wahab A; Zedet M; Labauge P; Tilikete C; Pique J; Tourbah A; Mathey G; Dimitri Boulos D; Branger P; Kremer LD; Marignier R; Collongues N; De Seze J
Eur J Neurol; 2021 Oct; 28(10):3461-3466. PubMed ID: 33103295
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
[TBL] [Abstract][Full Text] [Related]
17. Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
Nabizadeh F; Masrouri S; Sharifkazemi H; Azami M; Nikfarjam M; Moghadasi AN
J Clin Neurosci; 2022 Nov; 105():37-44. PubMed ID: 36075186
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of depression, anxiety, and sleep disturbances in patients with neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis.
Liu J; Zhang X; Zhong Y; Liu X
Mult Scler Relat Disord; 2023 Nov; 79():105007. PubMed ID: 37717305
[TBL] [Abstract][Full Text] [Related]
20. Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review.
Shahmohammadi S; Doosti R; Shahmohammadi A; Azimi A; Sahraian MA; Fattahi MR; Naser Moghadasi A
Mult Scler Relat Disord; 2021 Nov; 56():103227. PubMed ID: 34536774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
